Advanced Search

Study Preview



Study Title and Description

Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR).



Key Questions Addressed
3 Key Question 3. What are the harms of using medications to reduce risk for primary breast cancer? Key Question 3a. Do harms of risk-reducing medications vary by timing of initiation and/or duration of use? Key Question 3b. Do harms of risk-reducing medications persist beyond discontinuation of use?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR).
Author Runowicz CD., Costantino JP., Wickerham DL., Cecchini RS., Cronin WM., Ford LG., Vogel VG., Wolmark N.
Country National Surgical Adjuvant Breast and Bowel Project, National Cancer Institute, Pittsburgh, PA, USA. crunowic@fiu.edu
Year 2011
Numbers Pubmed ID: 21872200

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Key Questions 1-4


Results & Comparisons

No Results found.